LCAT Antibody (EPR1384Y)

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

The enzyme, lecithin cholesterol acyltransferase (LCAT), is responsible for the esterification of plasma cholesterol mediating the transfer of an acyl group from lecithin to the 3-hydroxy group of cholesterol (1). Esterification of cholesterol in plasma is mediated by LCAT. In patients with familial LCAT deficiency only trace amounts or no LCAT protein is found. Heterozygotes for this disorder have approximately half the normal amount of the enzyme. LCAT reactivity is essential for normal lipoprotein metabolism and for a proper equilibrium between tissue and plasma cholesterol (2). Cholesterol transport in circulation and its removal from tissues depends on the activity of lecithin cholesterol LCAT. LCAT is a soluble enzyme that converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lyso-phosphatidylcholines on the surface of high-density lipoproteins (3).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Showing Publication 1 - 1 of 1.

Publication using NB110-57158	Applications	Species
Bogan RL, Hennebold JD. The reverse cholesterol transport system as a potential mediator of luteolysis in the primate corpus luteum. Reproduction 2010-01-01 [PMID: 19776099]

Array NB110-57158

• LCAT Antibodies
• LCAT ELISA Kits
• LCAT Lysate
• LCAT Proteins